Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Fundamental Analysis

NASDAQ:RLYB - US75120L1008 - Common Stock

0.5775 USD
+0.02 (+3.59%)
Last: 9/3/2025, 8:00:01 PM
0.579 USD
+0 (+0.26%)
After Hours: 9/3/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RLYB. RLYB was compared to 542 industry peers in the Biotechnology industry. RLYB has a great financial health rating, but its profitability evaluates not so good. RLYB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RLYB had negative earnings in the past year.
In the past year RLYB has reported a negative cash flow from operations.
RLYB had negative earnings in each of the past 5 years.
In the past 5 years RLYB always reported negative operating cash flow.
RLYB Yearly Net Income VS EBIT VS OCF VS FCFRLYB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RLYB has a worse Return On Assets (-81.67%) than 69.37% of its industry peers.
RLYB has a Return On Equity (-90.62%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -81.67%
ROE -90.62%
ROIC N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
RLYB Yearly ROA, ROE, ROICRLYB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RLYB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLYB Yearly Profit, Operating, Gross MarginsRLYB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

RLYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RLYB has been increased compared to 1 year ago.
Compared to 5 years ago, RLYB has more shares outstanding
RLYB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLYB Yearly Shares OutstandingRLYB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RLYB Yearly Total Debt VS Total AssetsRLYB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -7.52, we must say that RLYB is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RLYB (-7.52) is worse than 67.71% of its industry peers.
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.52
ROIC/WACCN/A
WACC9.86%
RLYB Yearly LT Debt VS Equity VS FCFRLYB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

RLYB has a Current Ratio of 9.98. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
RLYB's Current ratio of 9.98 is amongst the best of the industry. RLYB outperforms 81.00% of its industry peers.
A Quick Ratio of 9.98 indicates that RLYB has no problem at all paying its short term obligations.
RLYB's Quick ratio of 9.98 is amongst the best of the industry. RLYB outperforms 81.00% of its industry peers.
Industry RankSector Rank
Current Ratio 9.98
Quick Ratio 9.98
RLYB Yearly Current Assets VS Current LiabilitesRLYB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

RLYB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.49%, which is quite impressive.
RLYB shows a strong growth in Revenue. In the last year, the Revenue has grown by 154.52%.
EPS 1Y (TTM)47.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
Revenue 1Y (TTM)154.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.1%

3.2 Future

Based on estimates for the next years, RLYB will show a small growth in Earnings Per Share. The EPS will grow by 2.36% on average per year.
RLYB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 165.51% yearly.
EPS Next Y35.78%
EPS Next 2Y19.69%
EPS Next 3Y12.55%
EPS Next 5Y2.36%
Revenue Next Year-19.74%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y165.51%

3.3 Evolution

RLYB Yearly Revenue VS EstimatesRLYB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2029 2030 2031 200M 400M 600M 800M
RLYB Yearly EPS VS EstimatesRLYB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RLYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RLYB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLYB Price Earnings VS Forward Price EarningsRLYB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLYB Per share dataRLYB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

RLYB's earnings are expected to grow with 12.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.69%
EPS Next 3Y12.55%

More info and screens

0

5. Dividend

5.1 Amount

RLYB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RALLYBIO CORP

NASDAQ:RLYB (9/3/2025, 8:00:01 PM)

After market: 0.579 +0 (+0.26%)

0.5775

+0.02 (+3.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)N/A N/A
Inst Owners67.89%
Inst Owner Change-2.57%
Ins Owners2.39%
Ins Owner Change0%
Market Cap24.13M
Analysts74.55
Price Target1.02 (76.62%)
Short Float %2.08%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.39%
Min EPS beat(2)11.96%
Max EPS beat(2)20.81%
EPS beat(4)4
Avg EPS beat(4)18.74%
Min EPS beat(4)11.96%
Max EPS beat(4)27.67%
EPS beat(8)7
Avg EPS beat(8)10.62%
EPS beat(12)10
Avg EPS beat(12)9.97%
EPS beat(16)12
Avg EPS beat(16)10.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-11.63%
EPS NQ rev (3m)28.32%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-1.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)162.78%
Revenue NY rev (3m)666%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.71
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-0.94
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.02
BVpS1.1
TBVpS1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.67%
ROE -90.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.98
Quick Ratio 9.98
Altman-Z -7.52
F-Score4
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)12.47%
Cap/Depr(5y)114.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.54%
EPS Next Y35.78%
EPS Next 2Y19.69%
EPS Next 3Y12.55%
EPS Next 5Y2.36%
Revenue 1Y (TTM)154.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.1%
Revenue Next Year-19.74%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y165.51%
EBIT growth 1Y43.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.43%
OCF growth 3YN/A
OCF growth 5YN/A